Work

A phase I study of selumetinib (AZD6244/ARRY-142866) in combination with cetuximab (cet) in refractory solid tumors and KRAS mutant colorectal cancer (CRC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.3103

Authors: Dustin A. Deming, William R. Schelman, Sam Joseph Lubner, Daniel Mulkerin, Noelle K. LoConte, Suzanne Fioravanti, Tim Greten, Jens C. Eickhoff, Jill Kolesar, Kathryn Compton, Laurence A Doyle, George Wilding, Austin G. Duffy, Glenn Liu

Institutions: University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, National Institutes of Health, National Cancer Institute

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603369132

Cites:

Cited by: 8

Related to: 10